A Unified Decision Framework for Phase I Dose-Finding Designs

11/24/2021
by   Yunshan Duan, et al.
0

The purpose of a phase I dose-finding clinical trial is to investigate the toxicity profiles of various doses for a new drug and identify the maximum tolerated dose. Over the past three decades, various dose-finding designs have been proposed and discussed, including conventional model-based designs, new model-based designs using toxicity probability intervals, and rule-based designs. We present a simple decision framework that can generate several popular designs as special cases. We show that these designs share common elements under the framework, such as the same likelihood function, the use of loss functions, and the nature of the optimal decisions as Bayes rules. They differ mostly in the choice of the prior distributions. We present theoretical results on the decision framework and its link to specific and popular designs like mTPI, BOIN, and CRM. These results provide useful insights into the designs and their underlying assumptions, and convey information to help practitioners select an appropriate design.

READ FULL TEXT

page 1

page 2

page 3

page 4

research
06/20/2020

A Unified Framework for Time-to-Event Dose-Finding Designs

In dose-finding trials, due to staggered enrollment, it might be desirab...
research
01/04/2019

The i3+3 Design for Phase I Clinical Trials

Purpose: The 3+3 design has been shown to be less likely to achieve the ...
research
04/24/2023

Generalized Likelihood Ratios for Understanding, Comparing and Constructing Interval Designs of Dose-Finding Studies

Dose-finding studies often include an up-and-down dose transition rule t...
research
11/15/2017

Bayesian optimal designs for dose-response curves with common parameters

The issue of determining not only an adequate dose but also a dosing fre...
research
05/14/2021

Improving the Performance of Bayesian Logistic Regression Model with Overdose Control in Oncology Dose-Finding Studies

An accurately identified maximum tolerated dose (MTD) serves as the corn...
research
04/30/2021

A Comparison of Model-Free Phase I Dose Escalation Designs for Dual-Agent Combination Therapies

It is increasingly common for therapies in oncology to be given in combi...
research
03/25/2021

The Ci3+3 Design for Dual-Agent Combination Dose-Finding Clinical Trials

We propose a rule-based statistical design for combination dose-finding ...

Please sign up or login with your details

Forgot password? Click here to reset